Physician profile
Marla Lambert
NPI 1508872557
$7,059.14
in general payments reported to CMS, 2019-2025
30 companies · $1,270 in 2025
The $1,270 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $1,070 · 2021: $1,137 · 2022: $1,045 · 2023: $762 · 2024: $1,276 · 2025: $1,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,308.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $959.59 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $916.53 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $793.19 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $781.90 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $503.61 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $500.18 | 2022-2025 | |
| Allergan, INC. | $443.23 | 2019-2020 | |
| Daiichi Sankyo INC. | $360.25 | 2021-2025 | Injectafer |
| Pfizer INC. | $357.84 | 2020-2025 | |
| Glaxosmithkline, LLC. | $339.23 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $246.51 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.91 | 2020-2021 | |
| Amarin Pharma, INC. | $97.70 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $94.14 | 2020-2022 | |
| Exact Sciences Corporation | $63.74 | 2023-2024 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $59.40 | 2022 | |
| Currax Pharmaceuticals LLC | $55.23 | 2022-2023 | Contrave, Onzetra Xsail, Nexlizet |
| Novartis Pharmaceuticals Corporation | $47.85 | 2022 | |
| Sumitomo Pharma America, INC. | $44.88 | 2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.34 | 2024 | Xifaxan |
| Biohaven Pharmaceutical Holding Company Ltd. | $32.88 | 2022 | |
| Radius Health, INC. | $32.49 | 2025 | Tymlos |
| Esperion Therapeutics, INC. | $30.80 | 2021 | |
| Merck Sharp & Dohme LLC | $30.35 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $29.41 | 2025 | Voquezna |
| Medtronic USA, INC. | $19.74 | 2019 | |
| Pbg Puerto Rico LLC | $17.99 | 2021 | |
| Mylan Specialty L.P. | $13.97 | 2024 | Yupelri |
| Ipsen Biopharmaceuticals, INC | $13.71 | 2024 | Iqirvo |
| Astellas Pharma US INC | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marla Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.